Vitreous Retina Macula Consultants of New York (VRMNY) has announced that they have been selected to participate in an innovative Wet AMD study in collaboration with Regenxbio. Wet age-related macular degeneration (wet AMD) is a severe visual impairment caused by the development of new leaky blood vessels in the retina, an essential tissue responsible for vision. VRMNY will be the only Manhattan-based site to participate in the study, which will offer an investigational therapy to patients.
The therapy is designed to deliver a targeted gene directly to the retina, in order for these cells to produce an anti-VEGF protein. This approach has the potential to reduce, or even eliminate, the frequent need for anti-VEGF injections, which are the current standard of care for wet AMD. For those interested in participating or learning more, VRMNY encourages scheduling an appointment with their dedicated research team.
This is a unique opportunity to be part of a study that could shape the future of wet AMD treatment.